Price Don’t Lie: How Analysts Feel About Dermira Inc After Today’s Huge Decline?

Price Don't Lie: How Analysts Feel About Dermira Inc After Today's Huge Decline?

The stock of Dermira Inc (NASDAQ:DERM) is a huge mover today! About 314,850 shares traded hands or 45.82% up from the average. Dermira Inc (NASDAQ:DERM) has risen 43.86% since April 13, 2016 and is uptrending. It has outperformed by 39.93% the S&P500.
The move comes after 5 months negative chart setup for the $1.21 billion company. It was reported on Nov, 15 by Barchart.com. We have $32.28 PT which if reached, will make NASDAQ:DERM worth $60.50 million less.

Dermira Inc (NASDAQ:DERM) Ratings Coverage

Out of 4 analysts covering Dermira Inc (NASDAQ:DERM), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dermira Inc has been the topic of 8 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Citigroup maintained the stock with “Buy” rating in Wednesday, March 16 report. The firm has “Buy” rating given on Friday, January 8 by Needham. As per Friday, December 18, the company rating was upgraded by Citigroup. Needham maintained the stock with “Buy” rating in Wednesday, May 11 report. The stock of Dermira Inc (NASDAQ:DERM) earned “Outperform” rating by Cowen & Co on Wednesday, August 19.

According to Zacks Investment Research, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California.”

Insitutional Activity: The institutional sentiment increased to 2.78 in Q2 2016. Its up 1.10, from 1.68 in 2016Q1. The ratio is positive, as 11 funds sold all Dermira Inc shares owned while 21 reduced positions. 35 funds bought stakes while 54 increased positions. They now own 29.11 million shares or 30.57% more from 22.30 million shares in 2016Q1.
Metropolitan Life Insur Communications Ny holds 0% or 15,819 shares in its portfolio. Dafna Mngmt Ltd Liability reported 193,642 shares or 4.49% of all its holdings. Commonwealth Of Pennsylvania Public School Empls Retrmt System owns 19,232 shares or 0.01% of their US portfolio. Blackrock Gp Ltd has invested 0% of its portfolio in Dermira Inc (NASDAQ:DERM). State Board Of Administration Of Florida Retirement, a Florida-based fund reported 8,727 shares. Tudor Invest Et Al accumulated 14,425 shares or 0.01% of the stock. Nationwide Fund accumulated 0% or 27,711 shares. Nicholas Prns Limited Partnership has 111,101 shares for 0.23% of their US portfolio. American Intll Grp holds 12,085 shares or 0% of its portfolio. Lombard Odier Asset Mngmt (Usa) reported 268,878 shares or 0.95% of all its holdings. The Massachusetts-based Cormorant Asset Ltd Co has invested 0.71% in Dermira Inc (NASDAQ:DERM). Retail Bank Of America De accumulated 128,338 shares or 0% of the stock. Jpmorgan Chase And has 3,558 shares for 0% of their US portfolio. Royal State Bank Of Canada holds 1,000 shares or 0% of its portfolio. Axa, a France-based fund reported 188,634 shares.

Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 22 insider sales for $4.26 million net activity. On Friday, July 15 the insider Griffith Christopher M. sold $39,116. $143,582 worth of Dermira Inc (NASDAQ:DERM) shares were sold by GUGGENHIME ANDREW. WIGGANS THOMAS G also sold $347,925 worth of Dermira Inc (NASDAQ:DERM) shares. 2,500 shares were sold by BAUER EUGENE A, worth $82,950 on Monday, August 1. $16,000 worth of Dermira Inc (NASDAQ:DERM) shares were sold by RINGO WILLIAM R.

More news for Dermira Inc (NASDAQ:DERM) were recently published by: Marketwatch.com, which released: “Dermira Inc. NASDAQ: DERM” on October 03, 2014. Investorplace.com‘s article titled: “3 Stocks to Watch on Thursday: Ciena Corporation (CIEN), Dermira Inc (DERM …” and published on June 02, 2016 is yet another important article.

DERM Company Profile

Dermira, Inc., incorporated on August 18, 2010, is a biopharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), in Phase III development for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase III development for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating, and DRM01, in Phase IIb development for the treatment of acne vulgaris, or acne. The Firm is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as psoriasis, hyperhidrosis and acne.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment